BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) scheduled CEO Seth Lederman, M.D., to give a 25-minute company presentation at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on Tuesday, November 10, 2026. The slot ran from 4:00 to 4:25 p.m. ET, and management also planned 1x1 investor meetings at the event, the company said in a November 4 announcement.
The company gave six days' notice, by our calculation, between the November 4 announcement and the conference date. It said a live webcast and a replay would be available under the News & Events tab in the Investors section of its website. Because the event date has passed, the replay is now the only route to the presentation. The announcement did not publish a slide deck or agenda.
Tonix names three marketed products and four pipeline candidates in its announcement
The company describes itself as a fully integrated, commercial-stage biopharmaceutical company. Its marketed products are TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), Zembrace SymTouch (sumatriptan injection 3 mg) and Tosymra (sumatriptan nasal spray 10 mg). Tonix calls TONMYA its flagship product and says it is the first medicine approved for fibromyalgia in more than 15 years. That is a company claim.
The pipeline named in the release has four candidates:
- TNX-102 SL, in Phase 2 studies for major depressive disorder and for acute stress disorder/acute stress reaction;
- TNX-4800, an anti-OspA monoclonal antibody for Lyme disease prevention in the U.S., which Tonix calls Phase 2-ready;
- TNX-801, a horsepox live-virus vaccine in development for mpox and smallpox;
- TNX-1500, an anti-CD40L monoclonal antibody for preventing kidney transplant rejection, also described as Phase 2-ready.
Tonix states that TNX-102 SL for these new indications is investigational. Efficacy and safety have not been established, and the drug is not approved for these uses.
Tonix's release lists TONMYA's commercial launch and the need for more financing among its stated risks
The forward-looking statements name the failure to successfully launch and commercialize TONMYA and any approved product as a risk. They also cite the company's need for additional financing, uncertainty over government or third-party payer reimbursement, and substantial competition. Tonix refers investors to its Form 10-K for the year ended December 31, 2025, which it filed with the SEC on March 12, 2026.
The company did not disclose any sales or revenue figures for TONMYA, Zembrace SymTouch or Tosymra.
Tonix listed Deborah Elson (Tonix) and Brian Korb (astr partners) as investor contacts, and Andrea Cohen (Sam Brown Inc.) as media contact.